Hepatocyte growth factor increases uptake of estradiol 17beta-D-glucuronide and Oatp1 protein level in rat hepatocytes.
Hepatocyte growth factor (HGF) ameliorates liver injuries in hepatectomized cholestatic rats. On the other hand, the protein level of organic anion-transporting polypeptide (Oatp1), which is responsible for the uptake of bile salts into hepatocytes, decreases in cholestatic humans and rats. However, the relationship between the ameliorative effects of HGF and the decrease in Oatp1 levels in cholestasis remains to be understood. Therefore, in order to investigate this relationship, we evaluated the effects of HGF on the function and protein level of Oatp1. HGF treatment significantly increased the uptake of radiolabeled estradiol 17beta-d-glucuronide ([(3)H]E(2)17betaG), a predominant Oatp1 substrate, in primary cultured rat hepatocytes. Additionally, there was an increase in the Oatp1 protein levels. The increased [(3)H]E(2)17betaG uptake was significantly inhibited by simultaneous incubation with the HGF receptor antibody and treatment with non-radiolabeled E(2)17betaG. However, inhibition by taurocholic acid, a Na(+)-taurocholate co-transporting polypeptide (Ntcp) substrate, was weaker than that caused by non-radiolabeled E(2)17betaG. Further, the increase was not altered by replacing Na(+) in the medium with Li(+). In the inhibition study, the increased [(3)H]E(2)17betaG uptake was inhibited by Oatp1 substrates, including bromosulfophthalein, ochratoxin A, and ouabain, but not by digoxin, which is an Oatp2-specific substrate. Furthermore, HGF did not alter the Oatp1 mRNA expression. In contrast, HGF treatment suppressed the ubiquitination of Oatp1 protein. In conclusion, this is the first report suggesting that HGF regulates Oatp1 protein level and that the ameliorative effects of HGF in cholestasis was induced, at least in part, by correcting the down-regulation of the Oatp1 protein level.
Iwakiri
Tomomi
T
Department of Pharmacy, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Miyazaki 889-1692, Japan.
Okumura
Manabu
M
Matsunaga
Naoya
N
Ichihara
Emi
E
Shiotsuki
Satoshi
S
Nagata
Masashi
M
Kumagai
Yuki
Y
Kai
Hirofumi
H
Arimori
Kazuhiko
K
D000818:Animals; D002478:Cells, Cultured; D002779:Cholestasis / Q000188:drug therapy* / Q000503:physiopathology; D004958:Estradiol / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D005786:Gene Expression Regulation / Q000187:drug effects; D017228:Hepatocyte Growth Factor / Q000502:physiology*; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism; D008297:Male; D029362:Organic Anion Transporters, Sodium-Independent / Q000187:drug effects* / Q000378:metabolism; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013656:Taurocholic Acid / Q000493:pharmacokinetics; D054875:Ubiquitination / Q000187:drug effects
D029362:Organic Anion Transporters, Sodium-Independent; D012333:RNA, Messenger; C421102:Slco1a1 protein, rat; C025483:estradiol-17 beta-glucuronide; D004958:Estradiol; D013656:Taurocholic Acid; D017228:Hepatocyte Growth Factor